公开(公告)号：JP2012139224A

公开(公告)日：2012-07-26

申请号：JP2012032142

申请日：2012-02-16

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： GHAYUR TARIQ ,  DIXON RICHARD W ,  ROGUSKA MIKE ,  WHITE MICHAEL ,  LABKOVSKY BORIS ,  SALFELD JOCHEN ,  DUNCAN ALEXANDER ROBERT ,  BROCKLEHURST SIMON MARK ,  MANKOVICH JOHN ,  SHORROCK CELIA PATRICIA ,  THOMPSON JULIA ELIZABETH ,  LENNARD SIMON NICHOLAS

IPC: C12N15/02 ,  C12N15/09 ,  A61K31/436 ,  A61K31/519 ,  A61K31/573 ,  A61K31/706 ,  A61K38/00 ,  A61K39/395 ,  A61K45/00 ,  A61P1/00 ,  A61P1/04 ,  A61P1/16 ,  A61P3/00 ,  A61P3/08 ,  A61P3/10 ,  A61P5/14 ,  A61P5/16 ,  A61P5/40 ,  A61P7/00 ,  A61P7/02 ,  A61P7/04 ,  A61P7/06 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P15/08 ,  A61P15/10 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P19/06 ,  A61P25/00 ,  A61P25/08 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P27/02 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/10 ,  A61P31/12 ,  A61P31/14 ,  A61P31/18 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/00 ,  A61P39/02 ,  A61P43/00 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  C40B40/10

CPC classification number: C07K16/244 ,  A61K31/519 ,  A61K31/56 ,  A61K38/13 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  A61K39/395 ,  A61K31/00

Abstract: PROBLEM TO BE SOLVED: To provide a perfect human antibody IL-18 as a preferred IL-18 inhibitor, because parts of a chimera and humanized antibodies still remain as a murine sequence, and therefore, may cause an undesirable immune reaction if they are administered over a long period.SOLUTION: The present invention includes an antigen binding to a human interleukin-18, particularly an antigen binding to an epitope of a human IL-18. The antibody can be, for example, an entirely human antibody, a recombinant antibody, or monoclonal antibody. A preferred antibody has the high affinity for the hIL-18, and/or neutralizes an hIL-18 activity in vitro and in vivo. The antibody can be of a full-length or an antigen binding portion thereof. The methods of making and using the antibody are also provided. The antibody, or the antibody portion is useful for detecting the hIL-18, and also useful, for example, for inhibiting a hIL-18 activity in a human subject suffering from a disorder in which the hIL-18 is detrimental.

Abstract translation: 要解决的问题：提供完美的人抗体IL-18作为优选的IL-18抑制剂，因为嵌合体和人源化抗体的一部分仍然保持为鼠序列，因此如果 它们长期施用。 解决方案：本发明包括与人白介素-18结合的抗原，特别是与人IL-18的表位结合的抗原。 抗体可以是例如完全人抗体，重组抗体或单克隆抗体。 优选的抗体对hIL-18具有高亲和力，和/或在体外和体内中和hIL-18活性。 抗体可以是全长或其抗原结合部分。 还提供了制备和使用抗体的方法。 抗体或抗体部分可用于检测hIL-18，并且还可用于例如在患有hIL-18有害的病症的人类受试者中抑制hIL-18活性。 版权所有（C）2012，JPO＆INPIT

公开(公告)号：ZA200206266B

公开(公告)日：2003-11-06

申请号：ZA200206266

申请日：2002-08-06

Applicant: ABBOTT LAB

Inventor： GHAYUR TARIQ ,  DIXON RICHARD W ,  ROGUSKA MIKE ,  WHITE MICHAEL ,  LABKOVSKY BORIS ,  SALFELD JOCHEN ,  DUNCAN ALEXANDER ROBERT ,  BROCKLEHURST SIMON MARK ,  MANKOVICH JOHN ,  SHORROCK CELIA PATRICIA ,  THOMPSON JULIA ELIZABETH ,  LENNARD SIMON NICHOLAS

IPC: A61K39/395 ,  C12N15/02 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/00 ,  A61P39/02 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  C07K

Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular, antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-I8 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

公开(公告)号：NZ520392A

公开(公告)日：2005-04-29

申请号：NZ52039201

申请日：2001-02-09

Applicant: ABBOTT LAB

Inventor： GHAYUR TARIQ ,  DIXON RICHARD W ,  ROGUSKA MIKE ,  WHITE MICHAEL ,  LABKOVSKY BORIS ,  SALFELD JOCHEN ,  DUNCAN ALEXANDER ROBERT ,  BROCKLEHURST SIMON MARK ,  MANKOVICH JOHN ,  SHORROCK CELIA PATRICIA ,  THOMPSON JULIA ELIZABETH ,  LENNARD SIMON NICHOLAS

IPC: A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  C12N15/02 ,  A61P3/10 ,  A61P5/14 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/00 ,  A61P39/02 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08

Abstract: An isolated human monoclonal antibody capable of binding to human IL-18 is described. The antibody can be used in the manufacture of a medicament for inhibiting human IL-18 activity, and for detecting human IL-18 activity in a sample.

公开(公告)号：PL356836A1

公开(公告)日：2004-07-12

申请号：PL35683601

申请日：2001-02-09

Applicant: ABBOTT LAB

Inventor： GHAYUR TARIQ ,  DIXON RICHARD W ,  ROGUSKA MIKE ,  WHITE MICHAEL ,  LABKOVSKY BORIS ,  SALFELD JOCHEN ,  DUNCAN ALEXANDER ROBERT ,  BROCKLEHURST SIMON MARK ,  MANKOVICH JOHN ,  SHORROCK CELIA PATRICIA ,  THOMPSON JULIA ELIZABETH ,  LENNARD SIMON NICHOLAS

IPC: A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  C12N15/02 ,  A61P5/14 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/00 ,  A61P39/02 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  C12N15/13

Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular, antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-I8 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

公开(公告)号：CA2399148A1

公开(公告)日：2001-08-16

申请号：CA2399148

申请日：2001-02-09

Applicant: ABBOTT LAB

Inventor： WHITE MICHAEL ,  SHORROCK CELIA PATRICIA ,  LABKOVSKY BORIS ,  MANKOVICH JOHN ,  BROCKLEHURST SIMON MARK ,  DUNCAN ALEXANDER ROBERT ,  SALFELD JOCHEN ,  GHAYUR TARIQ ,  DIXON RICHARD W ,  ROGUSKA MIKE ,  LENNARD SIMON NICHOLAS ,  THOMPSON JULIA ELIZABETH

IPC: C12N15/02 ,  A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/00 ,  A61P39/02 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  A61P1/00 ,  A61P3/00 ,  A61P5/00 ,  A61P9/00 ,  A61P13/00 ,  A61P19/00 ,  A61P21/00 ,  A61P25/00 ,  A61K38/13 ,  C12N15/13 ,  A61K38/17 ,  A61K31/445 ,  A61K31/505 ,  A61K31/56 ,  C12N15/85

Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particul ar antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutraliz e hIL-18 activityin vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject sufferin g from a disorder in which hIL-18 activity is detrimental.

公开(公告)号：AU2006252098B2

公开(公告)日：2011-02-24

申请号：AU2006252098

申请日：2006-12-18

Applicant: ABBOTT LAB

Inventor： MANKOVICH JOHN ,  GHAYUR TARIQ ,  SHORROCK CELIA ELIZABETH ,  BROCKLEHURST SIMON MARK ,  DUNCAN ALEXANDER ROBERT ,  LENNARD SIMON NICHOLAS ,  THOMPSON JULIA ELIZABETH ,  SALFELD JOCHEN ,  WHITE MICHAEL ,  LABKOVSKY BORIS ,  ROGUSKA MIKE ,  DIXON RICHARD W

IPC: C12N15/02 ,  A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/00 ,  A61P39/02 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08

Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular, antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-I8 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

公开(公告)号：AU2006252098A1

公开(公告)日：2007-01-11

申请号：AU2006252098

申请日：2006-12-18

Applicant: ABBOTT LAB

Inventor： MANKOVICH JOHN ,  GHAYUR TARIQ ,  SHORROCK CELIA ELIZABETH ,  BROCKLEHURST SIMON MARK ,  DUNCAN ALEXANDER ROBERT ,  LENNARD SIMON NICHOLAS ,  THOMPSON JULIA ELIZABETH ,  SALFELD JOCHEN ,  WHITE MICHAEL ,  LABKOVSKY BORIS ,  ROGUSKA MIKE ,  DIXON RICHARD W

IPC: C12N15/02 ,  A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/00 ,  A61P39/02 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08

Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular, antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-I8 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

公开(公告)号：BR0108188A

公开(公告)日：2003-02-25

申请号：BR0108188

申请日：2001-02-09

Applicant: ABBOTT LAB

Inventor： GHAYUR TARIQ ,  DIXON RICHARD W ,  ROGUSKA MIKE ,  WHITE MICHAEL ,  LABKOVSKY BORIS ,  SALFELD JOCHEN ,  DUNCAN ALEXANDER ROBERT ,  BROCKLEHURST SIMON MARK ,  MANKOVICH JOHN ,  SHORROCK CELIA PATRICIA ,  THOMPSON JULIA ELISABETH ,  LENNARD SIMON NICHOLAS

IPC: C12N15/02 ,  A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/00 ,  A61P39/02 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  C07K16/00

Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular, antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-I8 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

公开(公告)号：NO20023788D0

公开(公告)日：2002-08-09

申请号：NO20023788

申请日：2002-08-09

Applicant: ABBOTT LAB

Inventor： GHAYUR TARIQ ,  DIXON RICHARD WOODWARD ,  ROGUSKA MICHAEL ,  WHITE MICHAEL ,  LABKOVSKY BORIS ,  SALFELD JOCHEN G ,  DUNCAN ALEXANDER R ,  BROCKLEHURST SIMON MARK ,  MANKOVICH JOHN A ,  SHORROCK CELIA PATRICIA ,  THOMPSON JULIA ELIZABETH ,  LENNARD SIMON NICHOLAS

IPC: A61K39/395 ,  A61K45/00 ,  C12N15/02 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/00 ,  A61P39/02 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  C07K

Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular, antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-I8 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

公开(公告)号：AU2011201536A1

公开(公告)日：2011-04-28

申请号：AU2011201536

申请日：2011-04-05

Applicant: ABBOTT LAB

Inventor： DUNCAN ALEXANDER ROBERT ,  LABKOVSKY BORIS ,  SHORROCK CELIA ELIZABETH ,  SALFELD JOCHEN ,  MANKOVICH JOHN ,  ELIZABETH THOMPSON JULIA ,  WHITE MICHAEL ,  ROGUSKA MIKE ,  DIXON RICHARD W ,  BROCKLEHURST SIMON MARK ,  LENNARD SIMON NICHOLAS ,  GHAYUR TARIQ

IPC: C12N15/02 ,  A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/00 ,  A61P39/02 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08

Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular, antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-I8 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.